|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2 negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010 -01 ) 显示文摘 | Charehbili A van de Ven S Smit VT | 2014 | Ann Oncol2014，25，5： | 1 |
| 2 | Surgical/pathologicstage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries 显示文摘 | Bunt AM Hermans J Smit VT | 1995 | J Clin Oncol1995，13，1： | 1 |
| 3 | Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk(PORTEC-2):an open-label,non-inferiority,randomised trial显示文摘 | Nout RA Smit VT Putter H | 2010 | Lancet2010，375，9717： | 1 |
| 4 | Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast can- cer显示文摘 | Van de Ven S Smit VT Dekker TJ | 2011 | Cancer Treat Rev2011，37，6： | 1 |
| 5 | Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2) : an open-label, non- inferiority, randomised trial 显示文摘 | Nout RA Smit VT Putter H | 2010 | Lancet2010，375，9717： | 1 |
| 6 | Discordances in ER,PRand HER2 receptors after neoadjuvant chemotherapy in breast cancer显示文摘 | van de Ven S Smit VT Dekker TJ | 2011 | Cancer Treatment Re views2011，37，6： | 1 |
| 7 | KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas 显示文摘 | Smit VT Boot AJ Smits AM | 1988 | ucleic Acids Res1988，16，16： | 1 |
| 8 | Discordances in ER,PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer显示文摘 | van de Ven S Smit VT Dekker TJ | 2011 | Cancer Treatment Reviews2011，，37： | 1 |
| 9 | Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer 显示文摘 | Van DVS Smit VT Dekker TJ | 2011 | Cancer Treat Rev2011，37，： | 1 |
| 10 | Discordances in ER,PR and HER2receptors after neoadjuvant chemotherapy in breast cancer显示文摘 | van de Ven S Smit VT Dekker TJ | 2011 | Cancer Treat Rev2011，37，6： | 1 |
| 11 | Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer显示文摘 | van de Ven S Smit VT Dekker TJ | 2011 | Cancer Treat Rev2011，37，6： | 1 |
| 12 | Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer 显示文摘 | Van de Ven S Smit VT Dekker TJ | 2011 | Cancer Treat Rev2011，37，6： | 1 |
| 13 | Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer 显示文摘 | Van de Ven S Smit VT Dekker TJ | 2011 | Cancer Treat Rev2011，37，6： | 1 |
| 14 | Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrialcancer of high-intermediate risk (PORTEC-2) : an open-label, non - inferiority, randomised trial显示文摘 | Nout RA Smit VT Putter H | 2010 | Lancet2010，375，9717： | 1 |
| 15 | Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma显示文摘 | Scholten AN Smit VT Beerman H | 2004 | Cancer2004，100，： | 1 |
| 16 | Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer显示文摘 | van de Ven S Smit VT Dekker TJ | 2010 | Cancer Treat Rev2010，20，： | 1 |
| 17 | Addition of zoledronicacid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2 negative stageⅡ/Ⅲ breast cancer: The NEOZOTAC trial( BOOG 2010 -01 ) 显示文摘 | Charehbili A van de Ven S Smit VT | 2014 | Ann Onco12014，2，： | 1 |
| 18 | Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2):an open-label,non-inferiority,randomized trial显示文摘 | Nout RA Smit VT Putter H | | 0，，： | 1 |
| 19 | Disorganised stroma determined on pre-treatment breast cancer biopsies is associated with poor response to neoadjuvant cbemotherapy: Results from the Neozotac trial 显示文摘 | Dekker TJ Charehbili A Smit VT | 2015 | Mol Oncol2015，9，6： | 1 |
| 20 | Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk(PORTEC-2):an open-label,non-inferiority,randomised trial显示文摘 | Nout RA Smit VT Putter H | 2010 | Lancet2010，375，9717： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员